# Biotia

> Biotia is a New York-based health-tech company that fights infectious diseases by combining next-generation DNA sequencing with AI-driven software. Its metagenomic platform identifies bacteria, fungi, parasites and viruses - plus antimicrobial-resistance markers - from a single sample against a curated database of more than 16,000 microbial species. Spun out of the Jacobs Technion-Cornell Institute at Cornell Tech and operating a CLIA-certified lab in New York City, Biotia turns a single microbiome test into an actionable clinical report to help providers diagnose hard-to-detect infections and support pathogen surveillance from the hospital to outer space.

- **Founded:** 2016
- **Headquarters:** Long Island City, New York, United States
- **Founders:** Niamh B. O'Hara (Co-Founder & CEO), Christopher E. Mason (Co-Founder & Global Director), Rachid Ounit (Co-Founder)
- **Team size:** 26
- **Products:** BIOTIA-ID Urine, BIOTIA-ID Joint Fluid, BIOTIA-DX, BIOTIA-DX Resistance, Chelsea
- **Notable:** First genomics-based urine assay leveraging AI to be approved by the New York State Department of Health (BIOTIA-ID Urine)., BIOTIA-DX Resistance achieved the highest prediction accuracy in the 2025 CAMDA Antimicrobial Resistance Challenge., Raised an oversubscribed $8M Series A in 2022, led by OCA Ventures.

## Products & services

- **BIOTIA-ID Urine** — AI-driven shotgun metagenomic sequencing assay for identifying pathogens behind urinary tract infections; the first genomics-based urine assay leveraging AI approved by the New York State Department of Health.
- **BIOTIA-ID Joint Fluid** — Metagenomic diagnostic assay for detecting pathogens in joint-fluid samples to support diagnosis of joint and prosthetic infections.
- **BIOTIA-DX** — Health-systems diagnostic solution that applies metagenomic sequencing and AI to identify microorganisms and antimicrobial resistance from clinical samples.
- **BIOTIA-DX Resistance** — Antimicrobial-resistance prediction tool that achieved the highest prediction accuracy in the 2025 CAMDA AMR Challenge.
- **Chelsea** — Proprietary AI-powered software platform that identifies known and emerging bacteria, fungi, parasites and viruses plus AMR and virulence markers from a curated database of 16,000+ microbial species.
- **GeoSeeq** — Software platform for organizing, analyzing and sharing microbial-genomics data across research and surveillance projects.

## Achievements

- First genomics-based urine assay leveraging AI to be approved by the New York State Department of Health (BIOTIA-ID Urine).
- BIOTIA-DX Resistance achieved the highest prediction accuracy in the 2025 CAMDA Antimicrobial Resistance Challenge.
- Raised an oversubscribed $8M Series A in 2022, led by OCA Ventures.
- Signed a joint development agreement with Mayo Clinic.
- Built a clinically curated database of more than 16,000 microbial species.
- Founding team pioneered microbial exploration from the human body to the NYC subway to hospitals to outer space.

## Latest updates

- **2025** — BIOTIA-DX Resistance achieved the highest prediction accuracy in the 2025 CAMDA Antimicrobial Resistance Challenge.
- **2025** — Announced a joint development agreement with Mayo Clinic to enhance microbial diagnostics.
- **2023** — New York State Department of Health approved Biotia's AI- and sequencing-based urinary tract infection test.
- **2022-08** — Raised an oversubscribed $8M Series A led by OCA Ventures.

## Links

- Website: https://biotia.io
- LinkedIn: https://www.linkedin.com/company/biotia
- Twitter/X: https://twitter.com/BiotiaNYC
- Facebook: https://www.facebook.com/BiotiaNYC/

---

Profile page: https://yespress.io/biotia
Published by YesPress — https://yespress.io
Last updated: 2026-07-22